Trial
NCT05975645
A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Collaborators
—
Condition
Advanced Hepatocellular Carcinoma
Intervention
Penpulimab injection
Why stopped
This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-12